The roles of the CXCL12–CXCR4 axis in CML cell survival prompted several groups to examine the therapeutic efficacy of CXCR4 antagonists for CML in preclinical models. Here, CXCL12 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.